Edesa Biotech Inc
For the period ended Sep 30, 2024. Filed Dec 13, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Dec 13, 2024
EDSA$2.02-18.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets at September 30, 2024 and 2023
| September 30, 2024 | September 30, 2023 | |
|---|---|---|
| Assets: | ||
| Current assets: | ||
| Cash and cash equivalents | $1,037,320 | $5,361,397 |
| Accounts and other receivable | 270,908 | 626,543 |
| Prepaid expenses and other current assets | 367,394 | 448,912 |
| Total current assets | 1,675,622 | 6,436,852 |
| Non-current assets: | ||
| Property and equipment, net | - | 8,702 |
| Long-term deposits | 41,151 | 173,490 |
| Intangible asset, net | 2,078,848 | 2,180,020 |
| Right-of-use assets | 18,361 | 91,373 |
| Total assets | $3,813,982 | $8,890,437 |
| Liabilities and shareholders' equity: | ||
| Current liabilities: | ||
| Accounts payable and accrued liabilities | $1,812,960 | $1,747,150 |
| Short-term right-of-use lease liabilities | 19,867 | 74,714 |
| Total current liabilities | 1,832,827 | 1,821,864 |
| Non-current liabilities: | ||
| Long-term right-of-use lease liabilities | - | 19,773 |
| Total liabilities | 1,832,827 | 1,841,637 |
| Commitments (Note 7) | ||
| Shareholders' equity: | ||
| Capital shares | ||
| Authorized unlimited common and preferred shares without par value | ||
| Issued and outstanding: 3,247,389 common shares (September 30, 2023 - 3,075,473) | 47,236,024 | 46,643,151 |
| Additional paid-in capital | 13,576,757 | 13,039,265 |
| Accumulated other comprehensive loss | (242,613) | (214,648) |
| Accumulated deficit | (58,589,013) | (52,418,968) |
| Total shareholders' equity | 1,981,155 | 7,048,800 |
| Total liabilities and shareholders' equity | $3,813,982 | $8,890,437 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.